Table 4

Treatment-emergent adverse events in ≥3% of mITT subjects
Adverse Event Tigecycline Comparator
N = 268 N = 263
n (%) n (%)
Nausea* 117 (43.7) 44 (16.7)
Vomiting* 64 (23.9) 14 (5.3)
Diarrhea* 39 (14.6) 14 (5.3)
Constipation 17 (6.3) 22 (8.4)
Dyspepsia 17 (6.3) 7 (2.7)
Headache 20 (7.5) 22 (8.4)
Pain 15 (5.6) 18 (6.8)
Abdominal pain 17 (6.3) 7 (2.7)
Fever 9 (3.4) 6 (2.3)
Chest pain 6 (2.2) 8 (3.0)
Insomnia 22 (8.2) 17 (6.5)
Anxiety 9 (3.4) 7 (2.7)
Dizziness 9 (3.4) 6 (2.3)
Hypokalemia* 6 (2.2) 17 (6.5)
Pruritis 15 (5.6) 16 (6.1)
Hypertension 8 (3.0) 9 (3.4)
Anemia 8 (3.0) 7 (2.7)

*Significant between-group difference (p < 0.05). Pain was a general category for any pain without a more specific category (e.g., abdominal pain). mITT, modified intent-to-treat.

Matthews et al.

Matthews et al. BMC Infectious Diseases 2012 12:297   doi:10.1186/1471-2334-12-297

Open Data